Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
25.63
+0.04 (0.16%)
Jul 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 25.37 - 25.73
52 week 19.25 - 26.18
Open 25.66
Vol / Avg. 0.00/1.91M
Mkt cap 7.08B
P/E     -
Div/yield     -
EPS -4.23
Shares 276.32M
Beta 1.32
Inst. own 99%
Jul 30, 2014
Q3 2014 Hologic Inc Earnings Call - 4:30PM EDT - Add to calendar
Jul 30, 2014
Q3 2014 Hologic Earnings Release - 4:00PM EDT - Add to calendar
Jun 11, 2014
Hologic at Goldman Sachs Healthcare Conference
Apr 30, 2014
Q2 2014 Hologic Earnings Conference Call - Webcast
Apr 30, 2014
Q2 2014 Hologic Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -2.68% -47.06%
Operating margin 7.33% -36.73%
EBITD margin - 19.34%
Return on average assets -0.80% -12.04%
Return on average equity -3.42% -47.85%
Employees 5,615 -
CDP Score - -

Address

35 Crosby Drive
BEDFORD, MA 01730
United States - Map
+1-781-9997300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women. The Company's core business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company sells and service its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company offers a wide range of diagnostic products which are used primarily to aid in the diagnosis of human diseases and screen donated human blood. The Company's molecular diagnostics products include the Company's Aptima family of assays based on its Transcription-Mediated-Amplification, or TMA, technology, its Cervista products based on its Invader chemistry and its advanced instrumentation (Panther, Tigris and HTA).

Officers and directors

David R. LaVance Jr. Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Stephen P. MacMillan President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Glenn P. Muir Chief Financial Officer, Executive Vice President - Finance and Administration, Assistant Treasurer, Assistant Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert W. McMahon Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Casey Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Claus Egstrand Senior Vice President, General Manager - International
Bio & Compensation  - Reuters
Rohan F. Hastie Ph.D. Group Senior Vice President, General Manager - Diagnostics
Age: 39
Bio & Compensation  - Reuters
Roger D. Mills Group Senior Vice President, General Manager - Service and Operations
Age: 58
Bio & Compensation  - Reuters